Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2022-07-26 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
第四届董事会第三十五次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at a specific board meeting of Yunnan Watson Biotechnology Co., Ltd. It details the date and attendance of the board meeting, the agenda items discussed, voting results, and mentions independent directors' opinions and legal opinions. The content focuses on board decisions such as stock option plans, donations, and guarantees by subsidiaries. There are no financial statements or detailed financial performance data presented. The document is not a full annual or interim report, nor is it a call transcript or earnings release. It is clearly a Board/Management Information announcement about board meeting resolutions and decisions. The document length is short (1695 characters), consistent with a meeting resolution announcement rather than a full report. Therefore, the appropriate classification is MANG (Board/Management Information).
2022-07-26 Chinese
独立董事关于第四届董事会第三十五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on specific matters discussed at the 35th meeting of the 4th board of directors of Yunnan Watson Biotechnology Co., Ltd. It includes detailed opinions on stock option incentive plans, donations by a subsidiary, and guarantee letters for project payments. The content focuses on board-level decisions and approvals rather than financial results, earnings, or regulatory filings. There is no indication that this is a full annual report, audit report, or earnings release. The document is not a call transcript, capital update, or legal proceeding report. It is clearly related to board/management information, specifically independent directors' opinions on board meeting matters. The document length is short (1459 characters), consistent with a board/management announcement rather than a full report. Therefore, the most appropriate classification is Board/Management Information (MANG).
2022-07-26 Chinese
第四届监事会第二十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Yunnan Watson Biotechnology Co., Ltd. It details the decisions made during the 27th meeting of the 4th Supervisory Board, including approval of stock option exercise conditions, donation plans, and guarantee applications by subsidiaries. The document is a formal announcement of meeting resolutions rather than a full report or financial statement. It does not contain financial data or detailed management analysis but rather the outcomes of board deliberations. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2022-07-26 Chinese
北京国枫律师事务所关于公司2018年股票期权激励计划之预留授予股票期权第二个行权期行权条件成就的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the achievement of exercise conditions for the second exercise period of reserved stock options under the 2018 stock option incentive plan of Yunnan Watson Biotechnology Co., Ltd. It details the approval and decision-making procedures, the fulfillment of exercise conditions, and the legal compliance of the stock option plan. The document is a standalone legal opinion related to stock option incentives, not a full annual report, audit report, or financial statement. It is not an announcement of voting results, nor a management or board change announcement. It is a legal proceeding type document related to stock option incentive plan compliance and exercise conditions. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length is substantial (9576 characters), and it contains detailed legal analysis and opinions, not just a brief announcement or certification. Hence, the classification is LTR with high confidence.
2022-07-26 Chinese
2018年股票期权激励计划预留授予股票期权第二个行权期可行权激励对象名单
Board/Management Information Classification · 95% confidence The document is a detailed list of stock option incentive plan participants and allocations for the year 2018, including names, positions, and stock option quantities. It focuses on the distribution and exercise of stock options among core management and key personnel. There is no indication that this is a full annual or interim financial report, earnings release, or regulatory filing. It is not a notice of dividend, capital change, or share transaction. The content relates to management and board-level stock option incentives, which is typically classified under management or board information. Given the focus on stock option incentives for management and key personnel, the most appropriate classification is Board/Management Information (MANG). The document length is 2251 characters, which is relatively short but contains substantive data about management stock options rather than just an announcement or summary, so it is not a report publication announcement or regulatory filing. Confidence is high due to the clear focus on management stock option incentives.
2022-07-26 Chinese
关于子公司收到发明专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (735 characters) from a company about its subsidiary receiving invention patent certificates. It contains no financial data, no mention of financial results, no regulatory filings related to financial performance, and no meeting or voting information. It is an announcement of a corporate event related to intellectual property, not a report or detailed financial disclosure. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing or certification. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2022-07-15 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.